Dr Wong directs multi-disciplinary research programs with a staff of approximately 50+, comprising two Associate Professors, several Assistant Professors/Lecturers, postdoctoral research fellows, clinical fellows, graduate students, epidemiologists, a team of statisticians and database management, and clinical trials and research assistants. His research is supported by >US$30M in peer-reviewed grant funding from National Institutes of Health (NIH), USA, the National Health and Medical Research Council (NH&MRC), Australia, the Biomedical Medical Research Council (BMRC) and National Medical Research Council (NMRC), Singapore.
1. Retinal Vascular Imaging as a Biological Tool to Study Human Diseases
The objectives of this program, based concurrently at the Singapore Advanced Imaging Laboratory of Ocular Imaging (SAILOR), Singapore and Retinal Vascular Imaging Centre (RetVIC), Melbourne, are to develop state of the art ocular imaging methods to measure retinal vascular changes and other features and to correlate these changes with systemic diseases (diabetes, hypertension, stroke and heart disease) and eye diseases (diabetic retinopathy, AMD, glaucoma).
2. Population-based Studies on Eye Diseases
The objectives of this research program, the Singapore Epidemiology of Eye Disease (SEED) Program, are to capture population data on the prevalence, incidence, risk factors and impact of major eye diseases, including myopia, angle-closure glaucoma, cataract, diabetic retinopathy and age-related macular degeneration (AMD). This program comprises several population-based studies in Singapore, such as the Singapore Malay Eye Study (SiMES), the Singapore Indian Eye Study (SINDI), the Singapore Chinese Eye Study (SCES), and the Singapore Prospective Cohort Study Program (SP2).
3. Clinical and Translational Studies on Retinal Diseases
The objectives of this research program is to determine the clinical features, risk factors, and natural history of, and new therapeutic strategies for, the major retinal diseases, including diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusion. This program comprises several clinical studies in Singapore and Australia, including clinical trials.